Research ArticleArticle
Allosteric Noncompetitive Small Molecule Selective Inhibitors of CD45 Tyrosine Phosphatase Suppress T-Cell Receptor Signals and Inflammation In Vivo
Michael D. Perron, Shafinaz Chowdhury, Isabelle Aubry, Enrico Purisima, Michel L. Tremblay and H. Uri Saragovi
Molecular Pharmacology April 2014, 85 (4) 553-563; DOI: https://doi.org/10.1124/mol.113.089847
Michael D. Perron
Lady Davis Institute-Jewish General Hospital (M.P., S.C., H.U.S.), Departments of Pharmacology and Therapeutics (M.P., H.U.S.), Biochemistry (I.A., E.P., M.L.T.), and Oncology (H.U.S.), Goodman Cancer Research Center (M.L.T.), and Segal Cancer Center, McGill University, Montreal, Quebec, Canada (H.U.S.); and Biotechnology Research Institute, National Research Council Canada, Montreal, Quebec, Canada (E.P.)
Shafinaz Chowdhury
Lady Davis Institute-Jewish General Hospital (M.P., S.C., H.U.S.), Departments of Pharmacology and Therapeutics (M.P., H.U.S.), Biochemistry (I.A., E.P., M.L.T.), and Oncology (H.U.S.), Goodman Cancer Research Center (M.L.T.), and Segal Cancer Center, McGill University, Montreal, Quebec, Canada (H.U.S.); and Biotechnology Research Institute, National Research Council Canada, Montreal, Quebec, Canada (E.P.)
Isabelle Aubry
Lady Davis Institute-Jewish General Hospital (M.P., S.C., H.U.S.), Departments of Pharmacology and Therapeutics (M.P., H.U.S.), Biochemistry (I.A., E.P., M.L.T.), and Oncology (H.U.S.), Goodman Cancer Research Center (M.L.T.), and Segal Cancer Center, McGill University, Montreal, Quebec, Canada (H.U.S.); and Biotechnology Research Institute, National Research Council Canada, Montreal, Quebec, Canada (E.P.)
Enrico Purisima
Lady Davis Institute-Jewish General Hospital (M.P., S.C., H.U.S.), Departments of Pharmacology and Therapeutics (M.P., H.U.S.), Biochemistry (I.A., E.P., M.L.T.), and Oncology (H.U.S.), Goodman Cancer Research Center (M.L.T.), and Segal Cancer Center, McGill University, Montreal, Quebec, Canada (H.U.S.); and Biotechnology Research Institute, National Research Council Canada, Montreal, Quebec, Canada (E.P.)
Michel L. Tremblay
Lady Davis Institute-Jewish General Hospital (M.P., S.C., H.U.S.), Departments of Pharmacology and Therapeutics (M.P., H.U.S.), Biochemistry (I.A., E.P., M.L.T.), and Oncology (H.U.S.), Goodman Cancer Research Center (M.L.T.), and Segal Cancer Center, McGill University, Montreal, Quebec, Canada (H.U.S.); and Biotechnology Research Institute, National Research Council Canada, Montreal, Quebec, Canada (E.P.)
H. Uri Saragovi
Lady Davis Institute-Jewish General Hospital (M.P., S.C., H.U.S.), Departments of Pharmacology and Therapeutics (M.P., H.U.S.), Biochemistry (I.A., E.P., M.L.T.), and Oncology (H.U.S.), Goodman Cancer Research Center (M.L.T.), and Segal Cancer Center, McGill University, Montreal, Quebec, Canada (H.U.S.); and Biotechnology Research Institute, National Research Council Canada, Montreal, Quebec, Canada (E.P.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Selective Inhibitors of CD45 PTP
Michael D. Perron, Shafinaz Chowdhury, Isabelle Aubry, Enrico Purisima, Michel L. Tremblay and H. Uri Saragovi
Molecular Pharmacology April 1, 2014, 85 (4) 553-563; DOI: https://doi.org/10.1124/mol.113.089847
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement